The Maine Cancer Genomics Initiative (MCGI) is an alliance of Maine oncology providers led by The Jackson Laboratory with funding from the Harold Alfond™ Foundation. Its primary goal is to reduce disparities in access to advanced technologies for cancer care and precision medicine.
Want to learn more?
Contact UsMCGI, in partnership with every oncology practice in Maine, has provided innovative cancer genomic testing, education and clinical trials infrastructure to one of the most rural areas in the country. Now, MCGI has become a model for community precision oncology, or personalized cancer care, in a rural setting.
Latest News
-
Featured ArticleSeptember 15, 2022JAX undertakes nationwide study to evaluate impact of genomic tumor boards on cancer care
The Jackson Laboratory announced today that it will take its cornerstone genomic tumor board program to oncologists across the nation as part of a SWOG Cancer Research Network study, in collaboration with Columbia University. -
Featured ArticleFebruary 01, 2022MCGI: A 'game changer' for cancer patients
The Maine Cancer Genomics Initiative is raising awareness of, and access to, advanced genomic treatments all across Maine. -
Search MagazineJune 29, 2021When kids get cancer
The Maine Cancer Genomics Initiative is now working with pediatric oncologists to bring precision treatment approaches to young people with cancers. -
Press ReleaseOctober 08, 2020Maine Cancer Genomics Initiative expands; offers clinical trials and new technology
The Maine Cancer Genomics Initiative (MCGI), a collaboration aimed at making the latest personalized medicine available to cancer patients throughout Maine, will now bring new precision oncology clinical trials to the state, support access to targeted therapies for patients not eligible for trials, and develop novel technology to enhance genomic education and genetic services through online platforms.
-
Featured ArticleJune 28, 2022JAX Genomic Medicine is increasing the precision of brain cancer diagnoses
The new technique of methylome profiling, now available from The Jackson Laboratory, provides more precise tumor classification for cancers of the central nervous system (CNS). -
Press ReleaseOctober 14, 2021JAX appoints first ever Chief Medical Officer, Jens Rueter
Jens Rueter, M.D. has been appointed the first ever chief medical officer of The Jackson Laboratory. Rueter is a practicing physician in Maine and has served as medical director of JAX’s Maine Cancer Genomics Initiative (MCGI) for the past five years. -
Press ReleaseDecember 02, 2020JAX to expand advanced cancer clinical trial
JAX’s Maine Cancer Genomics Initiative joins nationwide TAPUR Study, providing access to targeted cancer therapies for rural population. -
Search MagazineJune 29, 2020Courageously pursuing knowledge
From cancer genomics testing to clinical trials, John Pierce is exploring the latest advances to address his medical issues.